

Daniel J. Müller

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9564561/daniel-j-muller-publications-by-citations.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

260
papers

9,532
citations

51
h-index

86
g-index

282
ext. papers

11,263
ext. citations

5.1
avg, IF

6.07
L-index

#	Paper	IF	Citations
260	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. <i>Clinical Pharmacology and Therapeutics</i> , 2015 , 98, 127-34	6.1	488
259	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. <i>Canadian Journal of Psychiatry</i> , 2016 , 61, 540-60	4.8	469
258	Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. <i>Clinical Pharmacology and Therapeutics</i> , 2013 , 93, 402-8 ¹	6.1	334
257	Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. <i>Clinical Pharmacology and Therapeutics</i> , 2017 , 102, 37-44	6.1	269
256	Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. <i>Current Drug Metabolism</i> , 2014 , 15, 209-17	3.5	265
255	Molecular mechanisms of schizophrenia. <i>Cellular Physiology and Biochemistry</i> , 2007 , 20, 687-702	3.9	214
254	Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. <i>Molecular Psychiatry</i> , 2012 , 17, 242-66	15.1	186
253	Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing. <i>Clinical Pharmacology and Therapeutics</i> , 2013 , 94, 324-8	6.1	168
252	Association between a functional polymorphism in the monoamine oxidase A gene promoter and major depressive disorder. <i>American Journal of Medical Genetics Part A</i> , 2000 , 96, 801-803		147
251	Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. <i>Archives of General Psychiatry</i> , 2012 , 69, 904-12		142
250	Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 103, 574-581	6.1	139
249	Genetics of antipsychotic treatment emergent weight gain in schizophrenia. <i>Pharmacogenomics</i> , 2006 , 7, 863-87	2.6	127
248	Evidence of association between smoking and alpha7 nicotinic receptor subunit gene in schizophrenia patients. <i>Neuropsychopharmacology</i> , 2004 , 29, 1522-6	8.7	123
247	Comprehensive allelotype and genetic analysis of 466 human nervous system tumors. <i>Journal of Neuropathology and Experimental Neurology</i> , 2000 , 59, 544-58	3.1	114
246	A genome screen for genes predisposing to bipolar affective disorder detects a new susceptibility locus on 8q. <i>Human Molecular Genetics</i> , 2001 , 10, 2933-44	5.6	113
245	Genes for emotion-enhanced remembering are linked to enhanced perceiving. <i>Psychological Science</i> , 2013 , 24, 2244-53	7.9	110
244	Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting. <i>Clinical Pharmacology and Therapeutics</i> , 2016 , 99, 172-85	6.1	100

243	MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes. <i>Nature Communications</i> , 2017 , 8, 15497	17.4	93
242	Systematic screening for DNA sequence variation in the coding region of the human dopamine transporter gene (DAT1). <i>Molecular Psychiatry</i> , 2000 , 5, 275-82	15.1	93
241	Brain-derived neurotrophic factor (BDNF) gene and rapid-cycling bipolar disorder: family-based association study. <i>British Journal of Psychiatry</i> , 2006 , 189, 317-23	5.4	92
240	Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis. <i>Pharmacogenomics</i> , 2010 , 11, 1561-71	2.6	89
239	Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis. <i>International Journal of Neuropsychopharmacology</i> , 2007 , 10, 697-704	5.8	88
238	A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia. <i>Neuropsychopharmacology</i> , 2010 , 35, 1315-24	8.7	84
237	The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia. <i>Neuroscience Letters</i> , 2005 , 379, 81-9	3.3	82
236	Neurogenetic variations in norepinephrine availability enhance perceptual vividness. <i>Journal of Neuroscience</i> , 2015 , 35, 6506-16	6.6	80
235	Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort. <i>BMC Psychiatry</i> , 2016 , 16, 105	4.2	80
234	Imaging and quantifying chemical and physical properties of native proteins at molecular resolution by force-volume AFM. <i>Angewandte Chemie - International Edition</i> , 2011 , 50, 12103-8	16.4	80
233	Towards the integration of pharmacogenetics in psychiatry: a minimum, evidence-based genetic testing panel. <i>Current Opinion in Psychiatry</i> , 2019 , 32, 7-15	4.9	77
232	Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. <i>Psychopharmacology</i> , 2005 , 181, 179-87	4.7	76
231	Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients. <i>Molecular Psychiatry</i> , 2007 , 12, 794-5	15.1	69
230	Familial occurrence of tardive dyskinesia. <i>Acta Psychiatrica Scandinavica</i> , 2001 , 104, 375-9	6.5	69
229	PharmGKB summary: carbamazepine pathway. <i>Pharmacogenetics and Genomics</i> , 2011 , 21, 906-10	1.9	64
228	Pharmacogenetics of antipsychotics. <i>Canadian Journal of Psychiatry</i> , 2014 , 59, 76-88	4.8	62
227	Oxytocin and oxytocin receptor gene polymorphisms and risk for schizophrenia: a case-control study. <i>World Journal of Biological Psychiatry</i> , 2013 , 14, 500-8	3.8	62
226	Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample. <i>Pharmacogenomics</i> , 2010 , 11, 773-80	2.6	62

225	Pharmacogenetics of antipsychotic-induced weight gain. <i>Pharmacological Research</i> , 2004 , 49, 309-29	10.2	61
224	Association between oxytocin receptor gene polymorphisms and self-rated empathic concern in schizophrenia. <i>PLoS ONE</i> , 2012 , 7, e51882	3.7	59
223	Association study of polymorphisms in leptin and leptin receptor genes with antipsychotic-induced body weight gain. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012 , 38, 134-41	5.5	58
222	Deletion variant in the ADRA2B gene increases coupling between emotional responses at encoding and later retrieval of emotional memories. <i>Neurobiology of Learning and Memory</i> , 2014 , 112, 222-9	3.1	57
221	The role of brain-derived neurotrophic factor (BDNF) gene variants in antipsychotic response and antipsychotic-induced weight gain. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012 , 39, 96-101	5.5	56
220	Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. <i>International Journal of Neuropsychopharmacology</i> , 2007 , 10, 639-51	5.8	56
219	Investigation of the human serotonin 6 (5-HT ₆) receptor gene in bipolar affective disorder and schizophrenia 2000 , 96, 217-221		56
218	Disturbed frontal gyrification within families affected with schizophrenia. <i>Journal of Psychiatric Research</i> , 2007 , 41, 805-13	5.2	55
217	Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 110, 888-896	6.1	55
216	Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant. <i>Pharmacogenomics Journal</i> , 2010 , 10, 200-18	3.5	54
215	Decreased frontal lobe ratio of N-acetyl aspartate to choline in familial schizophrenia: a proton magnetic resonance spectroscopy study. <i>Neuroscience Letters</i> , 2000 , 289, 147-51	3.3	54
214	The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment. <i>Frontiers in Neuroscience</i> , 2017 , 11, 741	5.1	53
213	Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options. <i>Pharmacotherapy</i> , 2014 , 34, 166-84	5.8	53
212	Neurexin-1 and frontal lobe white matter: an overlapping intermediate phenotype for schizophrenia and autism spectrum disorders. <i>PLoS ONE</i> , 2011 , 6, e20982	3.7	53
211	Suggestive association between the C825T polymorphism of the G-protein beta3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia. <i>European Neuropsychopharmacology</i> , 2005 , 15, 525-31	1.2	52
210	Pharmacogenetics of alcohol, nicotine and drug addiction treatments. <i>Addiction Biology</i> , 2011 , 16, 357-74	4.6	51
209	Pharmacogenetics and outcome with antipsychotic drugs. <i>Dialogues in Clinical Neuroscience</i> , 2014 , 16, 555-66	5.7	51
208	Antipsychotic induced weight gain: genetics, epigenetics, and biomarkers reviewed. <i>Current Psychiatry Reports</i> , 2014 , 16, 473	9.1	50

207	Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic. <i>International Review of Psychiatry</i> , 2013 , 25, 554-71	3.6	50
206	Analysis of the novel TPH2 gene in bipolar disorder and suicidality. <i>Molecular Psychiatry</i> , 2004 , 9, 896-7	15.1	50
205	Dopamine D3 receptor variant and tardive dyskinesia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2000 , 250, 31-5	5.1	50
204	Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder. <i>Pharmacogenomics Journal</i> , 2014 , 14, 176-81	3.5	49
203	A possible susceptibility locus for bipolar affective disorder in chromosomal region 10q25--q26. <i>Molecular Psychiatry</i> , 2001 , 6, 342-9	15.1	49
202	Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinone oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010 , 34, 50-6	5.5	48
201	The microbiome-gut-brain axis: implications for schizophrenia and antipsychotic induced weight gain. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2018 , 268, 3-15	5.1	47
200	Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia. <i>Journal of Psychiatric Research</i> , 2013 , 47, 1760-5	5.2	47
199	Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain. <i>Pharmacogenomics Journal</i> , 2012 , 12, 156-64	3.5	47
198	Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia. <i>American Journal of Medical Genetics Part A</i> , 2001 , 105, 498-501		47
197	Second generation antipsychotic-induced obsessive-compulsive symptoms in schizophrenia: a review of the experimental literature. <i>Current Psychiatry Reports</i> , 2014 , 16, 510	9.1	46
196	The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot study. <i>Journal of Affective Disorders</i> , 2018 , 227, 542-549	6.6	46
195	Association analyses of the DAOA/G30 and D-amino-acid oxidase genes in schizophrenia: further evidence for a role in schizophrenia. <i>NeuroMolecular Medicine</i> , 2007 , 9, 169-77	4.6	45
194	Clinical implications of pharmacogenomics for tardive dyskinesia. <i>Pharmacogenomics Journal</i> , 2004 , 4, 77-87	3.5	44
193	Catechol-O-Methyltransferase Val158Met Polymorphism and Clinical Response to Antipsychotic Treatment in Schizophrenia and Schizo-Affective Disorder Patients: a Meta-Analysis. <i>International Journal of Neuropsychopharmacology</i> , 2016 , 19,	5.8	43
192	Genetic association study between antipsychotic-induced weight gain and the melanocortin-4 receptor gene. <i>Pharmacogenomics Journal</i> , 2013 , 13, 272-9	3.5	43
191	Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia. <i>European Neuropsychopharmacology</i> , 2009 , 19, 317-28	1.2	43
190	Inflammatory Cytokines and Antipsychotic-Induced Weight Gain: Review and Clinical Implications. <i>Molecular Neuropsychiatry</i> , 2016 , 2, 1-14	4.9	42

189	Genetics of Common Antipsychotic-Induced Adverse Effects. <i>Molecular Neuropsychiatry</i> , 2016 , 2, 61-78	4.9	42
188	Association of the alpha 2A adrenergic receptor -1291C/G polymorphism and antipsychotic-induced weight gain in European-Americans. <i>Pharmacogenomics</i> , 2009 , 10, 1169-76	2.6	40
187	Family-based and case-control study of catechol-O-methyltransferase in schizophrenia among Palestinian Arabs. <i>American Journal of Medical Genetics Part A</i> , 2003 , 119B, 35-9		40
186	Review and Consensus on Pharmacogenomic Testing in Psychiatry. <i>Pharmacopsychiatry</i> , 2021 , 54, 5-17	2	40
185	Physicians' Opinions following pharmacogenetic testing for psychotropic medication. <i>Psychiatry Research</i> , 2015 , 229, 913-8	9.9	39
184	The pharmacogenetics of antipsychotic-induced adverse events. <i>Current Opinion in Psychiatry</i> , 2013 , 26, 144-50	4.9	39
183	KIBRA polymorphism is associated with individual differences in hippocampal subregions: evidence from anatomical segmentation using high-resolution MRI. <i>Journal of Neuroscience</i> , 2013 , 33, 13088-93	6.6	39
182	Association of a functional polymorphism in neuropeptide Y with antipsychotic-induced weight gain in schizophrenia patients. <i>Journal of Clinical Psychopharmacology</i> , 2013 , 33, 11-7	1.7	39
181	Family and case-control association study of the tumor necrosis factor-alpha (TNF-alpha) gene with schizophrenia and response to antipsychotic medication. <i>Psychopharmacology</i> , 2006 , 188, 171-82	4.7	39
180	Effect of age, weight, and CYP2C19 genotype on escitalopram exposure. <i>Journal of Clinical Pharmacology</i> , 2010 , 50, 62-72	2.9	38
179	Symptomatic and Functional Outcomes and Early Prediction of Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy in Patients With Major Depressive Disorder: A CAN-BIND-1 Report. <i>Journal of Clinical Psychiatry</i> , 2019 , 80,	4.6	38
178	Depression, antidepressants, and bone health in older adults: a systematic review. <i>Journal of the American Geriatrics Society</i> , 2014 , 62, 1434-41	5.6	37
177	ANK3, CACNA1C and ZNF804A gene variants in bipolar disorders and psychosis subphenotype. <i>World Journal of Biological Psychiatry</i> , 2011 , 12, 392-7	3.8	37
176	HTR2C haplotypes and antipsychotics-induced weight gain: X-linked multimarker analysis. <i>Human Psychopharmacology</i> , 2007 , 22, 463-7	2.3	37
175	Cognitive and psychosocial function in retired professional hockey players. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, 512-519	5.5	36
174	GWAS-based machine learning approach to predict duloxetine response in major depressive disorder. <i>Journal of Psychiatric Research</i> , 2018 , 99, 62-68	5.2	36
173	Serotonin transporter gene and adverse life events in adult ADHD. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008 , 147B, 1461-9	3.5	36
172	Moclobemide response in depressed patients: association study with a functional polymorphism in the monoamine oxidase A promoter. <i>Pharmacopsychiatry</i> , 2002 , 35, 157-8	2	36

171	Gene-gene interaction between MAOA and COMT in suicidal behavior: analysis in schizophrenia. <i>Brain Research</i> , 2006 , 1097, 26-30	3.7	35
170	Further evidence for age of onset being an indicator for severity in bipolar disorder. <i>Journal of Affective Disorders</i> , 2002 , 68, 343-5	6.6	35
169	The Effects of Video Games on Cognition and Brain Structure: Potential Implications for Neuropsychiatric Disorders. <i>Current Psychiatry Reports</i> , 2015 , 17, 71	9.1	34
168	Pharmacogenetics of antidepressant treatment in obsessive-compulsive disorder: an update and implications for clinicians. <i>Pharmacogenomics</i> , 2014 , 15, 1147-57	2.6	34
167	Major psychoses symptomatology: factor analysis of 2241 psychotic subjects. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2001 , 251, 193-8	5.1	34
166	Genetics of antipsychotic-induced weight gain: update and current perspectives. <i>Pharmacogenomics</i> , 2013 , 14, 2067-83	2.6	32
165	Pharmacogenetics of anxiolytic drugs. <i>Journal of Neural Transmission</i> , 2009 , 116, 667-77	4.3	32
164	CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients. <i>Pharmacopsychiatry</i> , 2003 , 36, 73-8	2	32
163	Pharmacogenetics of tardive dyskinesia: an updated review of the literature. <i>Pharmacogenomics</i> , 2016 , 17, 1339-51	2.6	32
162	Analysis of 34 candidate genes in bupropion and placebo remission. <i>International Journal of Neuropsychopharmacology</i> , 2013 , 16, 771-81	5.8	30
161	Norepinephrine Transporter Gene Variants and Remission From Depression With Venlafaxine Treatment in Older Adults. <i>American Journal of Psychiatry</i> , 2017 , 174, 468-475	11.9	29
160	Pharmacogenetics of obsessive-compulsive disorders. <i>Pharmacogenomics</i> , 2012 , 13, 71-81	2.6	29
159	Association between the DAOA/G72 gene and bipolar disorder and meta-analyses in bipolar disorder and schizophrenia. <i>Bipolar Disorders</i> , 2011 , 13, 198-207	3.8	29
158	Navigating the Labyrinth of Pharmacogenetic Testing: A Guide to Test Selection. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 309-312	6.1	28
157	Genetic Similarities between Compulsive Overeating and Addiction Phenotypes: A Case for "Food Addiction"? <i>Current Psychiatry Reports</i> , 2015 , 17, 96	9.1	28
156	Preliminary evidence for association of genome-wide significant DRD2 schizophrenia risk variant with clozapine response. <i>Pharmacogenomics</i> , 2016 , 17, 103-9	2.6	28
155	The AmpliChip [®] CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism. <i>Genetic Testing and Molecular Biomarkers</i> , 2012 , 16, 897-903	1.6	27
154	Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients. <i>Pharmacogenomics Journal</i> , 2009 , 9, 168-74	3.5	27

153	Association study of polymorphisms in insulin induced gene 2 (INSIG2) with antipsychotic-induced weight gain in European and African-American schizophrenia patients. <i>Human Psychopharmacology</i> , 2010 , 25, 253-9	2.3	27
152	Genome-wide association study on antipsychotic-induced weight gain in the CATIE sample. <i>Pharmacogenomics Journal</i> , 2016 , 16, 352-6	3.5	27
151	The role of genetic variation across IL-1 β , IL-2, IL-6, and BDNF in antipsychotic-induced weight gain. <i>World Journal of Biological Psychiatry</i> , 2015 , 16, 45-56	3.8	26
150	Pharmacogenetics of clozapine treatment response and side-effects in schizophrenia: an update. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015 , 11, 1709-31	5.5	26
149	Genetic association analysis of the glutathione peroxidase (GPX1) gene polymorphism (Pro197Leu) with tardive dyskinesia. <i>Psychiatry Research</i> , 2006 , 141, 123-8	9.9	25
148	Association study between variants of AMP-activated protein kinase catalytic and regulatory subunit genes with antipsychotic-induced weight gain. <i>Journal of Psychiatric Research</i> , 2012 , 46, 462-8	5.2	24
147	A hypothesis-driven association study of 28 nuclear-encoded mitochondrial genes with antipsychotic-induced weight gain in schizophrenia. <i>Neuropsychopharmacology</i> , 2014 , 39, 1347-54	8.7	24
146	Genetic study of eight AKT1 gene polymorphisms and their interaction with DRD2 gene polymorphisms in tardive dyskinesia. <i>Schizophrenia Research</i> , 2008 , 106, 248-52	3.6	24
145	Role of 5-HT(2C) receptor gene variants in antipsychotic-induced weight gain. <i>Pharmacogenomics and Personalized Medicine</i> , 2011 , 4, 83-93	2.1	23
144	The catechol-O-methyl-transferase gene in tardive dyskinesia. <i>World Journal of Biological Psychiatry</i> , 2010 , 11, 803-12	3.8	23
143	Association study of cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia. <i>Pharmacogenomics Journal</i> , 2012 , 12, 260-6	3.5	23
142	Pharmacogenetics in Psychiatry: An Update on Clinical Usability. <i>Frontiers in Pharmacology</i> , 2020 , 11, 575540	5.6	23
141	Association of orexin receptor polymorphisms with antipsychotic-induced weight gain. <i>World Journal of Biological Psychiatry</i> , 2016 , 17, 221-9	3.8	22
140	Correlation of a set of gene variants, life events and personality features on adult ADHD severity. <i>Journal of Psychiatric Research</i> , 2010 , 44, 598-604	5.2	22
139	Association between a polymorphism in the pseudoautosomal X-linked gene SYBL1 and bipolar affective disorder. <i>American Journal of Medical Genetics Part A</i> , 2002 , 114, 74-8		22
138	Different negative priming impairments in schizophrenia and subgroups of obsessive-compulsive disorder. <i>Psychological Medicine</i> , 2002 , 32, 459-68	6.9	22
137	The Canadian Biomarker Integration Network in Depression (CAN-BIND): magnetic resonance imaging protocols. <i>Journal of Psychiatry and Neuroscience</i> , 2019 , 44, 223-236	4.5	22
136	PharmGKB summary: clozapine pathway, pharmacokinetics. <i>Pharmacogenetics and Genomics</i> , 2018 , 28, 214-222	1.9	22

135	Genetic testing as a supporting tool in prescribing psychiatric medication: Design and protocol of the IMPACT study. <i>Journal of Psychiatric Research</i> , 2018 , 96, 265-272	5.2	21
134	Methylenetetrahydrofolate reductase gene variants and antipsychotic-induced weight gain and metabolic disturbances. <i>Journal of Psychiatric Research</i> , 2014 , 54, 36-42	5.2	21
133	The uncanny return of the race concept. <i>Frontiers in Human Neuroscience</i> , 2014 , 8, 836	3.3	21
132	The putative functional rs1045881 marker of neurexin-1 in schizophrenia and clozapine response. <i>Schizophrenia Research</i> , 2011 , 132, 121-4	3.6	20
131	Caught in the trio trap? Potential selection bias inherent to association studies using parent-offspring trios. <i>American Journal of Medical Genetics Part A</i> , 2001 , 105, 351-3		20
130	Low-Dose Lithium Stabilizes Human Endothelial Barrier by Decreasing MLC Phosphorylation and Universally Augments Cholinergic Vasorelaxation Capacity in a Direct Manner. <i>Frontiers in Physiology</i> , 2016 , 7, 593	4.6	20
129	Exome sequence analysis of Finnish patients with clozapine-induced agranulocytosis. <i>Molecular Psychiatry</i> , 2014 , 19, 403-5	15.1	19
128	Gene-gene interaction analyses between NMDA receptor subunit and dopamine receptor gene variants and clozapine response. <i>Pharmacogenomics</i> , 2011 , 12, 277-91	2.6	19
127	Suicide attempts in schizophrenia and affective disorders with relation to some specific demographical and clinical characteristics. <i>European Psychiatry</i> , 2005 , 20, 65-9	6	19
126	Pharmacogenetics of antipsychotic treatment in schizophrenia. <i>Methods in Molecular Biology</i> , 2014 , 1175, 557-87	1.4	19
125	Genetic testing for CYP2D6 and CYP2C19 suggests improved outcome for antidepressant and antipsychotic medication. <i>Psychiatry Research</i> , 2019 , 279, 111-115	9.9	19
124	Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants. <i>Translational Psychiatry</i> , 2019 , 9, 254	8.6	18
123	Genetics and personalized medicine in antidepressant treatment. <i>Current Pharmaceutical Design</i> , 2012 , 18, 5853-78	3.3	18
122	Genetic variation in CYP3A43 is associated with response to antipsychotic medication. <i>Journal of Neural Transmission</i> , 2015 , 122, 29-34	4.3	17
121	Association study between two variants in the DOPA decarboxylase gene in bipolar and unipolar affective disorder. <i>American Journal of Medical Genetics Part A</i> , 2002 , 114, 519-22		17
120	Pharmacogenetics of Antipsychotic Drug Treatment: Update and Clinical Implications. <i>Molecular Neuropsychiatry</i> , 2020 , 5, 1-26	4.9	17
119	Association study of the tryptophan hydroxylase gene and bipolar affective disorder using family-based internal controls. <i>American Journal of Medical Genetics Part A</i> , 2000 , 96, 310-1		16
118	Pharmacogenetic Testing Options Relevant to Psychiatry in Canada: Options de tests pharmacogénétiques pertinents en psychiatrie au Canada. <i>Canadian Journal of Psychiatry</i> , 2020 , 65, 521-530	4.8	15

117	Genetic association analysis of N-methyl-D-aspartate receptor subunit gene GRIN2B and clinical response to clozapine. <i>Human Psychopharmacology</i> , 2016 , 31, 121-34	2.3	15
116	Genetic variation in the serotonin transporter and HTR1B receptor predicts reduced bone formation during serotonin reuptake inhibitor treatment in older adults. <i>World Journal of Biological Psychiatry</i> , 2014 , 15, 404-10	3.8	15
115	C-reactive protein and cardiovascular risk in bipolar disorder patients: A systematic review. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017 , 79, 442-451	5.5	15
114	The influence of dopamine-related genes on perceptual stability. <i>European Journal of Neuroscience</i> , 2013 , 38, 3378-83	3.5	15
113	Neural markers of genetic vulnerability to drug addiction. <i>Current Topics in Behavioral Neurosciences</i> , 2010 , 3, 277-99	3.4	15
112	A differential impact of lithium on endothelium-dependent but not on endothelium-independent vessel relaxation. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016 , 67, 98-106	5.5	15
111	Genome-wide association studies of placebo and duloxetine response in major depressive disorder. <i>Pharmacogenomics Journal</i> , 2018 , 18, 406-412	3.5	14
110	Fat mass- and obesity-associated (FTO) gene and antipsychotic-induced weight gain: an association study. <i>Neuropsychobiology</i> , 2014 , 69, 59-63	4	14
109	Association study of polymorphisms in cholecystokinin gene and its receptors with antipsychotic induced weight gain in schizophrenia patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010 , 34, 1484-90	5.5	14
108	The intersection of pharmacology, imaging, and genetics in the development of personalized medicine. <i>Dialogues in Clinical Neuroscience</i> , 2009 , 11, 363-76	5.7	14
107	Early change in reward and punishment sensitivity as a predictor of response to antidepressant treatment for major depressive disorder: a CAN-BIND-1 report. <i>Psychological Medicine</i> , 2019 , 49, 1629-1638	6.9	14
106	Association study of GABAA α receptor subunit gene variants in antipsychotic-associated weight gain. <i>Journal of Clinical Psychopharmacology</i> , 2015 , 35, 7-12	1.7	13
105	Genetic variation in IL-1 β , IL-2, IL-6, TSPO and BDNF and response to duloxetine or placebo treatment in major depressive disorder. <i>Pharmacogenomics</i> , 2015 , 16, 1919-29	2.6	13
104	Reduced accuracy accompanied by reduced neural activity during the performance of an emotional conflict task by unmedicated patients with major depression: A CAN-BIND fMRI study. <i>Journal of Affective Disorders</i> , 2019 , 257, 765-773	6.6	13
103	A comprehensive analysis of mitochondrial genes variants and their association with antipsychotic-induced weight gain. <i>Schizophrenia Research</i> , 2017 , 187, 67-73	3.6	13
102	Investigation of TSPO variants in schizophrenia and antipsychotic treatment outcomes. <i>Pharmacogenomics</i> , 2015 , 16, 5-22	2.6	13
101	Exploratory study on association of genetic variation in TBC1D1 with antipsychotic-induced weight gain. <i>Human Psychopharmacology</i> , 2013 , 28, 183-7	2.3	12
100	Association study of the gamma-aminobutyric acid type a receptor gamma2 subunit gene with schizophrenia. <i>Schizophrenia Research</i> , 2009 , 114, 33-8	3.6	12

99	Further evidence of MAO-A gene variants associated with bipolar disorder. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2007 , 144B, 37-40	3.5	12
98	The role of the ITIH3 rs2535629 variant in antipsychotic response. <i>Schizophrenia Research</i> , 2016 , 176, 131-135	3.6	12
97	Molecular mechanisms in lithium-associated renal disease: a systematic review. <i>International Urology and Nephrology</i> , 2016 , 48, 1843-1853	2.3	12
96	Investigation of the Gene in Tardive Dyskinesia - New Data and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2018 , 9, 974	5.6	12
95	No evidence for a role of the peroxisome proliferator-activated receptor gamma (PPARG) and adiponectin (ADIPOQ) genes in antipsychotic-induced weight gain. <i>Psychiatry Research</i> , 2014 , 219, 255-60	3.9	11
94	Genetic variation in the GCG and in the GLP1R genes and antipsychotic-induced weight gain. <i>Pharmacogenomics</i> , 2014 , 15, 423-31	2.6	11
93	Childhood Abuse History in Depression Predicts Better Response to Antidepressants with Higher Serotonin Transporter Affinity: A Pilot Investigation. <i>Neuropsychobiology</i> , 2016 , 74, 78-83	4	11
92	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels.. <i>Pharmacopsychiatry</i> , 2021 , 55,	2	11
91	Pharmacogenetic Analysis of Functional Glutamate System Gene Variants and Clinical Response to Clozapine. <i>Molecular Neuropsychiatry</i> , 2017 , 2, 185-197	4.9	10
90	Linking unfounded beliefs to genetic dopamine availability. <i>Frontiers in Human Neuroscience</i> , 2015 , 9, 521	3.3	10
89	Relation between cerebrospinal fluid, gray matter and white matter changes in families with schizophrenia. <i>Journal of Psychiatric Research</i> , 2006 , 40, 646-55	5.2	10
88	Predicting Worsening Suicidal Ideation With Clinical Features and Peripheral Expression of Messenger RNA and MicroRNA During Antidepressant Treatment. <i>Journal of Clinical Psychiatry</i> , 2019 , 80,	4.6	10
87	Impact of histamine receptors H1 and H3 polymorphisms on antipsychotic-induced weight gain. <i>World Journal of Biological Psychiatry</i> , 2018 , 19, S97-S105	3.8	9
86	Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: a 10-week open-label study. <i>Pharmacogenetics and Genomics</i> , 2017 , 27, 1-6	1.9	8
85	Towards precision medicine in generalized anxiety disorder: Review of genetics and pharmaco(epi)genetics. <i>Journal of Psychiatric Research</i> , 2019 , 119, 33-47	5.2	8
84	The effect of obesity, macronutrients, fasting and nutritional status on drug-metabolizing cytochrome P450s: a systematic review of current evidence on human studies. <i>European Journal of Nutrition</i> , 2021 , 60, 2905-2921	5.2	8
83	Older molecular brain age in severe mental illness. <i>Molecular Psychiatry</i> , 2021 , 26, 3646-3656	15.1	8
82	Pharmacogenetic Implications for Antidepressant Pharmacotherapy in Late-Life Depression: A Systematic Review of the Literature for Response, Pharmacokinetics and Adverse Drug Reactions. <i>American Journal of Geriatric Psychiatry</i> , 2020 , 28, 609-629	6.5	8

81	Role of synaptosome-related (SNARE) genes in adults with attention deficit hyperactivity disorder. <i>Psychiatry Research</i> , 2014 , 215, 799-800	9.9	8
80	Genetic interactions in the adrenergic system genes: analysis of antipsychotic-induced weight gain. <i>Human Psychopharmacology</i> , 2011 , 26, 386-91	2.3	8
79	Apolipoprotein E epsilon 4 and clinical phenotype in schizophrenia. <i>Lancet, The</i> , 1997 , 350, 1857-8	40	8
78	Identification of a naturally occurring 21 bp deletion in alpha 2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatment. <i>Pharmacological Research</i> , 2005 , 51, 381-4	10.2	8
77	Overview: Towards individualized treatment in schizophrenia. <i>Drug Development Research</i> , 2003 , 60, 75-94	5.1	8
76	International Consortium on the Genetics of Electroconvulsive Therapy and Severe Depressive Disorders (Gen-ECT-ic). <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020 , 270, 921-932	5.1	8
75	Clinical implications of APOE genotyping for late-onset Alzheimer's disease (LOAD) risk estimation: a review of the literature. <i>Journal of Neural Transmission</i> , 2019 , 126, 65-85	4.3	8
74	Genetic validation study of protein tyrosine phosphatase receptor type D (PTPRD) gene variants and risk for antipsychotic-induced weight gain. <i>Journal of Neural Transmission</i> , 2019 , 126, 27-33	4.3	8
73	Genetic study of neuregulin 1 and receptor tyrosine-protein kinase erbB-4 in tardive dyskinesia. <i>World Journal of Biological Psychiatry</i> , 2019 , 20, 91-95	3.8	8
72	From the Origins of Pharmacogenetics to First Applications in Psychiatry. <i>Pharmacopsychiatry</i> , 2020 , 53, 155-161	2	8
71	Pharmacogenetic guidelines and decision support tools for depression treatment: application to late-life. <i>Pharmacogenomics</i> , 2018 , 19, 1269-1284	2.6	8
70	Protein kinase cAMP-dependent regulatory type II beta (PRKAR2B) gene variants in antipsychotic-induced weight gain. <i>Human Psychopharmacology</i> , 2014 , 29, 330-5	2.3	7
69	Functional cortical effects of novel allelic variants of the serotonin transporter gene-linked polymorphic region (5-HTTLPR) in humans. <i>Pharmacopsychiatry</i> , 2007 , 40, 191-5	2	7
68	The Gut Microbiome in Schizophrenia and the Potential Benefits of Prebiotic and Probiotic Treatment. <i>Nutrients</i> , 2021 , 13,	6.7	7
67	Association Study of the Complement Component C4 Gene in Tardive Dyskinesia. <i>Frontiers in Pharmacology</i> , 2019 , 10, 1339	5.6	7
66	Investigation of the Gut Microbiome in Patients with Schizophrenia and Clozapine-Induced Weight Gain: Protocol and Clinical Characteristics of First Patient Cohorts. <i>Neuropsychobiology</i> , 2020 , 79, 5-12	4	7
65	Association study between the neurexin-1 gene and tardive dyskinesia. <i>Human Psychopharmacology</i> , 2017 , 32, e2568	2.3	6
64	New insights into tardive dyskinesia genetics: Implementation of whole-exome sequencing approach. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019 , 94, 109659	5.5	6

63	Association study of Disrupted-In-Schizophrenia-1 gene variants and tardive dyskinesia. <i>Neuroscience Letters</i> , 2018 , 686, 17-22	3.3	6
62	No evidence for association between NOTCH4 and schizophrenia in a large family-based and case-control association analysis. <i>Psychiatric Genetics</i> , 2006 , 16, 197-203	2.9	6
61	Genetics of schizophrenia: current strategies. <i>Clinical Neuroscience Research</i> , 2003 , 3, 5-16		6
60	Affective symptomatology in schizophrenia: a risk factor for tardive dyskinesia?. <i>European Psychiatry</i> , 2001 , 16, 71-4	6	6
59	Childhood maltreatment and cognitive functioning in patients with major depressive disorder: a CAN-BIND-1 report. <i>Psychological Medicine</i> , 2020 , 50, 2536-2547	6.9	6
58	Pharmacogenetic evaluation of a DISP1 gene variant in antidepressant treatment of obsessive-compulsive disorder. <i>Human Psychopharmacology</i> , 2018 , 33, e2659	2.3	6
57	Genome-wide association study on antipsychotic-induced weight gain in Europeans and African-Americans. <i>Schizophrenia Research</i> , 2019 , 212, 204-212	3.6	5
56	Association between the -2548G/A polymorphism of the leptin gene and antipsychotic-induced weight gain: Analysis of the CATIE sample and meta-analysis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020 , 102, 109952	5.5	5
55	Verbal memory improvement in first-episode psychosis - Δ carriers: a pleiotropic effect?. <i>Neuropsychiatric Disease and Treatment</i> , 2017 , 13, 2945-2953	3.1	5
54	Investigation of melanocortin system gene variants in antipsychotic-induced weight gain. <i>World Journal of Biological Psychiatry</i> , 2014 , 15, 251-8	3.8	5
53	Genetics of antipsychotic drug outcome and implications for the clinician: into the limelight. <i>Translational Developmental Psychiatry</i> , 2014 , 2, 24663		5
52	Genetic research with intermediate phenotypes: phenocopies, perspectives and pitfalls. <i>Addiction</i> , 2007 , 102, 1696-7	4.6	5
51	Etiopathogenetic mechanisms in long-term course of schizophrenia. <i>Pharmacopsychiatry</i> , 2004 , 37 Suppl 2, S136-40	2	5
50	Association Between Side Effects and Blood microRNA Expression Levels and Their Targeted Pathways in Patients With Major Depressive Disorder Treated by a Selective Serotonin Reuptake Inhibitor, Escitalopram: A CAN-BIND-1 Report. <i>International Journal of Neuropsychopharmacology</i> , 2020 , 23, 88-95	5.8	5
49	Reliability of a functional magnetic resonance imaging task of emotional conflict in healthy participants. <i>Human Brain Mapping</i> , 2020 , 41, 1400-1415	5.9	5
48	Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant response. <i>Translational Psychiatry</i> , 2021 , 11, 127	8.6	5
47	Economic evaluation in psychiatric pharmacogenomics: a systematic review. <i>Pharmacogenomics Journal</i> , 2021 , 21, 533-541	3.5	5
46	Validation study of microRNAs previously associated with antidepressant response in older adults treated for late-life depression with venlafaxine. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020 , 100, 109867	5.5	4

45	Association Study of Serotonin 3 Receptor Subunit Gene Variants in Antipsychotic-Induced Weight Gain. <i>Neuropsychobiology</i> , 2016 , 74, 169-175	4	4
44	Structural covariance pattern abnormalities of insula in major depressive disorder: A CAN-BIND study report. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021 , 111, 110194	5.5	4
43	Pharmacogenetics-Guided Advances in Antipsychotic Treatment. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 110, 582-588	6.1	4
42	Schizophrenia-associated gene dysbindin-1 and tardive dyskinesia. <i>Drug Development Research</i> , 2021 , 82, 678-684	5.1	3
41	No evidence for linkage by transmission disequilibrium test analysis of microsatellite marker D22S278 and schizophrenia in a Palestinian Arab and in a German population. <i>American Journal of Medical Genetics Part A</i> , 2001 , 105, 328-31		3
40	THE DEPRESSION INVENTORY DEVELOPMENT SCALE: Assessment of Psychometric Properties Using Classical and Modern Measurement Theory in a CAN-BIND Trial. <i>Innovations in Clinical Neuroscience</i> , 2020 , 17, 30-40	1	3
39	Machine learning in the prediction of depression treatment outcomes: a systematic review and meta-analysis.. <i>Psychological Medicine</i> , 2021 , 51, 2742-2751	6.9	3
38	Frequencies of Genetic Polymorphisms of Clinically Relevant Gene-Drug Pairs in a German Psychiatric Inpatient Population. <i>Pharmacopsychiatry</i> , 2021 , 54, 81-89	2	3
37	Escitalopram ameliorates differences in neural activity between healthy comparison and major depressive disorder groups on an fMRI Emotional conflict task: A CAN-BIND-1 study. <i>Journal of Affective Disorders</i> , 2020 , 264, 414-424	6.6	3
36	Contributions of cholinergic receptor muscarinic 1 and CYP1A2 gene variants on the effects of plasma ratio of clozapine/N-desmethylclozapine on working memory in schizophrenia. <i>Journal of Psychopharmacology</i> , 2021 , 35, 31-39	4.6	3
35	Multisite Comparison of MRI Defacing Software Across Multiple Cohorts. <i>Frontiers in Psychiatry</i> , 2021 , 12, 617997	5	3
34	Pharmacogenetics in Psychiatry: A Companion, Rather Than Competitor, to Protocol-Based Care. <i>JAMA Psychiatry</i> , 2018 , 75, 1090	14.5	3
33	Exploring brain connectivity changes in major depressive disorder using functional-structural data fusion: A CAN-BIND-1 study. <i>Human Brain Mapping</i> , 2021 , 42, 4940-4957	5.9	3
32	A systematic review on neuromodulation therapies for reducing body weight in patients with obesity. <i>Obesity Reviews</i> , 2021 , 22, e13309	10.6	3
31	Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial.. <i>Translational Psychiatry</i> , 2022 , 12, 101	8.6	3
30	Gene-drug pairings for antidepressants and antipsychotics: level of evidence and clinical application. <i>Molecular Psychiatry</i> , 2021 ,	15.1	2
29	Liver enzyme gene and tardive dyskinesia. <i>Pharmacogenomics</i> , 2020 , 21, 1065-1072	2.6	2
28	The Safety and Efficacy of Microbial Ecosystem Therapeutic-2 in People With Major Depression: Protocol for a Phase 2, Double-Blind, Placebo-Controlled Study. <i>JMIR Research Protocols</i> , 2021 , 10, e31439	2	2

27	Reviewing pharmacogenetics to advance precision medicine for opioids. <i>Biomedicine and Pharmacotherapy</i> , 2021 , 142, 112060	7.5	2
26	Ketamine Treatment in Depression: A Systematic Review of Clinical Characteristics Predicting Symptom Improvement. <i>Current Topics in Medicinal Chemistry</i> , 2020 , 20, 1398-1414	3	1
25	Accelerated brain aging in major depressive disorder and antidepressant treatment response: A CAN-BIND report. <i>NeuroImage: Clinical</i> , 2021 , 32, 102864	5.3	1
24	Visual QC Protocol for FreeSurfer Cortical Parcellations from Anatomical MRI		1
23	Regulation of melanocortin-4-receptor (MC4R) expression by SNP rs17066842 is dependent on glucose concentration. <i>European Neuropsychopharmacology</i> , 2020 , 37, 39-48	1.2	1
22	Pharmacogenomic Studies in Intellectual Disabilities and Autism Spectrum Disorder: A Systematic Review: Études Pharmacogénomiques en Déficiences Intellectuelles et Trouble du Spectre de L'Autisme: Une Revue Systématique. <i>Canadian Journal of Psychiatry</i> , 2020 , 706743720971950	4.8	1
21	Impacts on Quality of Life with Escitalopram Monotherapy and Aripiprazole Augmentation in Patients with Major Depressive Disorder: A CAN-BIND Report. <i>Pharmacopsychiatry</i> , 2021 , 54, 225-231	2	1
20	Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study Report. <i>CNS Drugs</i> , 2021 , 35, 439-450	6.7	1
19	Replication of machine learning methods to predict treatment outcome with antidepressant medications in patients with major depressive disorder from STAR*D and CAN-BIND-1. <i>PLoS ONE</i> , 2021 , 16, e0253023	3.7	1
18	Genome-Wide Association Study of Sleep Disturbances in Depressive Disorders. <i>Molecular Neuropsychiatry</i> , 2020 , 5, 34-43	4.9	1
17	Pharmacogenetic/Pharmacogenomic Tests for Treatment Prediction in Depression. <i>Advances in Experimental Medicine and Biology</i> , 2021 , 1305, 231-255	3.6	1
16	Baseline functional connectivity in resting state networks associated with depression and remission status after 16 weeks of pharmacotherapy: A CAN-BIND Report		1
15	Treatment-emergent and trajectory-based peripheral gene expression markers of antidepressant response. <i>Translational Psychiatry</i> , 2021 , 11, 439	8.6	1
14	Baseline Functional Connectivity in Resting State Networks Associated with Depression and Remission Status after 16 Weeks of Pharmacotherapy: A CAN-BIND Report. <i>Cerebral Cortex</i> , 2021 ,	5.1	1
13	Association between a functional polymorphism in the monoamine oxidase A gene promoter and major depressive disorder 2000 , 96, 801		1
12	Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review. <i>Therapeutic Advances in Psychopharmacology</i> , 2022 , 12, 204512532210965	4.9	1
11	Getting to precision psychopharmacology: Combining clinical and genetic information to predict fat gain from aripiprazole. <i>Journal of Psychiatric Research</i> , 2019 , 114, 67-74	5.2	0
10	Encountering Pharmacogenetic Test Results in the Psychiatric Clinic. <i>Canadian Journal of Psychiatry</i> , 2021 , 7067437211058847	4.8	0

9	Cognitive Outcomes with Sequential Escitalopram Monotherapy and Adjunctive Aripiprazole Treatment in Major Depressive Disorder: A Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report. <i>CNS Drugs</i> , 2021 , 35, 291-304	6.7	o
8	Changes in RNA expression levels during antidepressant treatment: a systematic review. <i>Journal of Neural Transmission</i> , 2021 , 128, 1461-1477	4.3	o
7	Hypothalamus volume and DNA methylation of stress axis genes in major depressive disorder: A CAN-BIND study report. <i>Psychoneuroendocrinology</i> , 2021 , 132, 105348	5	o
6	Common Data Elements to Facilitate Sharing and Re-use of Participant-Level Data: Assessment of Psychiatric Comorbidity Across Brain Disorders.. <i>Frontiers in Psychiatry</i> , 2022 , 13, 816465	5	
5	Pharmacogenetics of Serious Antipsychotic Side Effects 2016 , 21-38		
4	Opportunities and challenges of implementation models of pharmacogenomics in clinical practice 2020 , 449-457		
3	Genetic testing in psychiatry: State of the evidence 2020 , 437-448		
2	Feasibility and Efficacy of a Psychological Therapy for Patients With a Schizophrenic Psychosis in an Inpatient Setting: Study Protocol of a Randomized Switch Controlled Trial. <i>Frontiers in Public Health</i> , 2020 , 8, 391	6	
1	Association between the expression of lncRNA BASP-AS1 and volume of right hippocampal tail moderated by episode duration in major depressive disorder: a CAN-BIND 1 report. <i>Translational Psychiatry</i> , 2021 , 11, 469	8.6	